"Rescue" Regimens After Helicobacter Pylori Treatment Failure
Overview
Authors
Affiliations
Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a "rescue" treatment depends on which treatment is used initially. If a clarithromycin-based regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third "rescue" option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.
Dirjayanto V, Audrey J, Simadibrata D World J Gastroenterol. 2024; 30(10):1280-1286.
PMID: 38596495 PMC: 11000074. DOI: 10.3748/wjg.v30.i10.1280.
Research on antibiotic resistance in : a bibliometric analysis of the past decade.
Yuan C, Yu C, Sun Q, Xiong M, Zhou S, Zeng M Front Microbiol. 2023; 14:1208157.
PMID: 37389333 PMC: 10301835. DOI: 10.3389/fmicb.2023.1208157.
Dieye Y, Nguer C, Thiam F, Diouara A, Fall C Antibiotics (Basel). 2022; 11(12).
PMID: 36551358 PMC: 9774608. DOI: 10.3390/antibiotics11121701.
Sue S, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S JGH Open. 2021; 5(2):307-311.
PMID: 33553672 PMC: 7857288. DOI: 10.1002/jgh3.12492.
Rifabutin for the Treatment of Infection: A Review.
Gisbert J Pathogens. 2020; 10(1).
PMID: 33379336 PMC: 7823349. DOI: 10.3390/pathogens10010015.